Subscribe to RSS
DOI: 10.1055/s-0041-1736638
Infections Deaths in the PLATO Trial
Abstract
Background Cardiovascular benefits of aggressive dual antiplatelet therapy may be associated with extra risks including bleeding, cancer, and infections discovered first for prasugrel in the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel (TRITON) trial. Ticagrelor in PLATO also caused slightly more infections but surprisingly less sepsis-related deaths (SRD) than clopidogrel. However, verified infection fatalities in PLATO were lacking from the public domain. We obtained the complete Food and Drug Administration (FDA)-issued primary causes death list, matched it with the few local site records dataset and analyzed the patterns of infections and deaths reported in PLATO.
Methods Among infections, the FDA spreadsheet contains only two primary death codes for pneumonia (12–2) and SRD (12–8). We obtained local evidence for two pneumonia and two SRD and matched those with the FDA records. We assessed how SRD patterns were reported among nonvascular death's dataset.
Results The FDA PLATO records indicate that clopidogrel caused numerically less (n = 8) primary pneumonia deaths than ticagrelor (n = 10) but over three times more SRD (n = 23/7). Among matched verifiable outcomes, both pneumonia deaths were correct, but two clopidogrel SRD were incorrect. Of the remaining 21 clopidogrel SRD, 6 were reported as two separate closed paired entries in Brazil (lines 76 and 78 and 86 and 88) and India (lines 436 and 440), suggesting last minute addition of potentially incorrect SRD reports. Four ticagrelor SRD (lines 24,193,467 and 650) were “compensated” with close or next in line clopidogrel SRD entries (lines 22,195,468 and 651).
Conclusion The FDA-issued evidence suggests no benefit of ticagrelor in preventing deaths from infections with slightly more pneumonia deaths, with possible misreporting of SRD in PLATO. These findings require an in-depth precise review of sepsis deaths in this trial.
Publication History
Received: 05 August 2021
Accepted: 20 September 2021
Article published online:
08 November 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Kipshidze N, Platonova E, DiNicolantonio JJ, Kuliczkowski W, Serebruany VL. Excessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger?. Am J Ther 2015; 22 (02) e22-e27
- 2 Ramsdale DR, Aziz S, Newall N, Palmer N, Jackson M. Bacteremia following complex percutaneous coronary intervention. J Invasive Cardiol 2004; 16 (11) 632-634
- 3 Leroy O, Martin E, Prat A. et al. Fatal infection of coronary stent implantation. Cathet Cardiovasc Diagn 1996; 39 (02) 168-170 , discussion 171
- 4 Gross AK, Dunn SP, Feola DJ. et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013; 35 (02) 147-154
- 5 Blasco-Colmenares E, Perl TM, Guallar E. et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009; 169 (08) 788-796
- 6 Center for drug evaluation and research. Application number: 22-307. Assessed September 9, 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022307s000_sumr.pdf
- 7 The FDA ticagrelor review of complete response. Assessed August 20, 2020 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf
- 8 Varenhorst C, Alström U, Scirica BM. et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60 (17) 1623-1630
- 9 Varenhorst C, Alström U, Braun OO. et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart 2014; 100 (22) 1762-1769
- 10 Storey RF, James SK, Siegbahn A. et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014; 25 (07) 517-525
- 11 Serebruany V, Tanguay J-F, Benavides MA. et al; Clinical Trials Outcomes Verification Task Force. Verifying death reports in the platelet inhibition and patient outcomes (PLATO) trial. Am J Ther 2020; l 27 (06) e563-e572
- 12 Serebruany VL, Tanguay J-F, Marciniak TA. The FDA and PLATO Investigators death lists: call for a match. Int J Clin Pract 2021; l 75 (07) e14105
- 13 Serebruany V, Tanguay J-F. Misreported cancer deaths in PLATO trial. J Clin Med 2021; 10 (14) 3140
- 14 Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015; 114 (03) 490-497
- 15 Sexton TR, Zhang G, Macaulay TE. et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci 2018; 3 (04) 435-449
- 16 Omarjee L, Meilhac O, Perrot F, Janin A, Mahe G. Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?. Clin Immunol 2020; 216: 108468
- 17 Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics 2020; 21 (12) 889-897
- 18 Aït Mokhtar O, Gaubert M, Laine M. et al. Pleiotropic effects of ticagrelor: myth or reality?. Arch Cardiovasc Dis 2016; 109 (8-9): 445-448
- 19 Jeong HS, Kim JH, Hong SJ. Pleiotropic effects of ticagrelor beyond its potent antiplatelet effects contributing to additional clinical benefits. JACC Cardiovasc Interv 2018; 11 (17) 1785